GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » N4 Pharma PLC (STU:0GO) » Definitions » Debt-to-Revenue

N4 Pharma (STU:0GO) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is N4 Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

N4 Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. N4 Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. N4 Pharma's annualized Revenue for the quarter that ended in Dec. 2023 was €0.00 Mil. N4 Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


N4 Pharma Debt-to-Revenue Historical Data

The historical data trend for N4 Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

N4 Pharma Debt-to-Revenue Chart

N4 Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A -

N4 Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A -

Competitive Comparison of N4 Pharma's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, N4 Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


N4 Pharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, N4 Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where N4 Pharma's Debt-to-Revenue falls into.



N4 Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

N4 Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

N4 Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


N4 Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of N4 Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


N4 Pharma (STU:0GO) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec.

N4 Pharma (STU:0GO) Headlines

No Headlines